Table 4.
Vaccination cost inputs.
| Parameter | Base Case | Uncertainty Range | Source | |
|---|---|---|---|---|
| Low | High | |||
| Price of vaccine doses (USD) | ||||
| CECOLIN | 0.20 | - | 2.90 * | [16] |
| CERVARIX | 0.20 | - | 5.18 * | |
| GARDASIL-4 | 0.20 | - | 4.50 * | |
| Handling and delivery (% of price) | ||||
| % International handling | 3.0 | 2.4 | 3.60 | [51] |
| % International delivery | 10.0 | 8.0 | 12.0 | |
| Wastage percentage (%) | ||||
| CECOLIN | 5.0 | 3.8 | 6.3 | [16] |
| CERVARIX ** | 10.0 | 3.8 | 6.3 | |
| GARDASIL-4 | 5.0 | 3.8 | 6.3 | |
| Other costs | ||||
| Syringe price per dose (USD) | 0.05 | 0.04 | 0.06 | [16] |
| Syringe percentage wastage (%) | 10.0 | 8.0 | 12.0 | [20] |
| Costs of safety box per dose (USD) | 0.01 | 0.01 | 0.01 | [16] |
| Incremental Cost for delivery (USD) *** | ||||
| Costs per dose (2023–2031)) | 3.76 | 3.0 | 4.5 | [52] |
* Vaccine price without Gavi financing. ** CERVARIX wastage was assumed to be higher than the other vaccines, due to a multi-dose vial presentation. *** Includes Cold chain, planning and training, social mobilization, supervision, and service delivery, which was the biggest ingredient accounting for 24% of the total incremental delivery cost.